BASF increases prices for pharmaceutical excipients and active ingredients

BASF increases prices for pharmaceutical excipients and active ingredients
2011-08-29
P-11-392
Effective September 1, 2011, BASF will increase the sales prices globally for all pharmaceutical excipients and generic active pharmaceutical ingredients by 10%. 
 

This price increase affects the entire excipients portfolio including all binders, disintegrants, coatings, solubilizers, and solvents. The affected generic active pharmaceutical ingredient (API) portfolio contains products like Ibuprofen, Caffeine, and Pseudoephedrine.

 

Due to the continued rise in costs for raw materials, energy and labor this price increase has become necessary. All existing contractual obligations will be honored.

 

About BASF's Pharma Ingredients & Services

BASF produces and markets a broad range of active ingredients and excipients, as well as exclusive synthesis services for the pharmaceutical industry. These products are made using the latest technologies, to the highest quality standards and in compliance with cGMP guidelines. Further information can be found at www.pharmaingredients.basf.com.

 

About BASF

BASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products, and agricultural products to oil and gas. As a reliable partner BASF creates chemistry to help its customers in virtually all industries to be more successful. With its high-value products and intelligent solutions, BASF plays an important role in finding answers to global challenges such as climate protection, energy efficiency, nutrition and mobility. BASF posted sales of more than €63.9 billion in 2010 and had approximately 109,000 employees as of the end of the year. Further information on BASF is available on the Internet at www.basf.com or in the Social Media Newsroom at www.newsroom.basf.com.

 

Suggested Articles

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.

Interruptions continue to wreak havoc on the global drug supply as drugmakers respond to the detection of impurities in some commonly used meds.

Activist investor Caligan wants to rework the board of AMAG, the maker of female libido med Vyleesi, but the company isn’t giving up yet.